Skip to main content
padlock icon - secure page this page is secure

The Upshot of PI3K Inhibitors as Anticancer Arsenal: A Short Review

Buy Article:

$68.00 + tax (Refund Policy)

Background: The phophatidylinositol 3-kinase (PI3K) pathway is critical in regulating diverse cellular functions and its deregulation is associated to one third of human cancers. Therefore, several PI3K inhibitors have been developed with many of these entering preclinical and early clinical assessments. Structure based design has led to the development of broad array of agents including dual inhibitors of PI3K and mTOR, pan-PI3K inhibitors and isoform specific inhibitors for cancer therapy. However, as we move towards deeper clinical assessment, there are challenges with regards to therapeutic index, toxicity profile, overcoming feedback loops and the like. This review explores these classes of PI3K inhibitors, their strategies and progress in clinical assessment.

Method: A structured search of bibliographic databases was undertaken for peer-reviewed literature using a focused review query. The quality of retrieved articles was assessed using standard tools. The contents of the screened articles were ananlyzed to deduce interventions and findings extracting the quintessence in a conceptual framework.

Results: A total of 104 papers have been referenced in the review that includes research papers, review articles, conferences/meetings proceedings and theses. The papers were studied and assessed according to our objective and classified for the refinement of the data to be extracted from them. This review identifies classes of PI3K inhibitors and the status of these inhibitors in terms of its clinical value.

Conclusion: This review precisely talks about the finding and strategies of PI3K inhibitors in clinical development. Though the future of PI3K inhibitors against cancer might seem beaming, there are challenges to face regarding strategic development, clinical regimen, tolerability and limited monotherapy activity.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anticancer drugs; PI3K inhibitors; PI3K/ mTOR; clinical trials; combination therapy; isoform-specific PI3K; pan-PI3K

Document Type: Review Article

Publication date: December 1, 2018

More about this publication?
  • The journal aims to provide updates to researchers about new bioactive compounds with proven activities in various biological screenings and pharmacological models. The journal will contain information about the structures, biological activities and sources of chemical entities discovered or designed by researchers and published in leading journals. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia.

    The journal should prove to be essential reading for pharmacologists, pharmaceutical chemists and medicinal chemists who wish to be kept informed and up-to-date with the latest and most important developments about new bioactive compounds of natural or synthetic origin, including recent patents.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more